ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

HOUSTON and VANCOUVER, Sept. 28, 2019 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s lead Investigational New Drug (“IND”)…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.